New hope for rare fat disorder: daily leptin shots target blood sugar and fats

NCT ID NCT05164341

Ongoing Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a daily injection of metreleptin (a lab-made leptin hormone) can improve blood sugar and fat levels in people with partial lipodystrophy, a rare condition where fat is distributed abnormally. About 69 participants will receive either metreleptin or a placebo for 12 months. The main goals are to see if the drug lowers HbA1c and triglycerides.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

metreleptin (a lab-made version of the hormone leptin)

What this could lead to

If successful, this could provide a new treatment option to help control blood sugar and triglycerides in people with partial lipodystrophy.

What could go wrong

This is a relatively small Phase 3 trial, and results may not apply to all patients. Metreleptin requires daily injections and may cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired partial lipodystrophy familial partial lipodystrophy partial lipodystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARTIAL LIPODYSTROPHY

Contacts and locations

Show contact details

Locations

Amryt Research Site, Endocrinology Research Associates Inc

Columbus, Ohio, 43201, United States
Care Access Clinic

Sydney, Nova Scotia, B1M 0A1, Canada
Ecogene-21

Chicoutimi, Quebec, G7H 7K9, Canada
Emory University

Atlanta, Georgia, 30329, United States
Faculty of Medicine, Universite Laval

Québec, Quebec, G1V4W2, Canada
Flourish Boca Raton

Boca Raton, Florida, 33431, United States
Hadassah University Hospital - Ein Kerem

Jerusalem, Israel
Hamilton General Hospital- McMaster University

Hamilton, Ontario, L8N 3Z5, Canada
Hospital das Clinicas FMRP-USP

Ribeirão Preto, Brazil
Insight Centro de Pesquisas

Porto Alegre, Brazil
Instituto Estadual de Diabetes e Endocrinologia (IEDE-RJ)

Rio de Janeiro, Brazil
Leids Universitair Medisch Centrum

Leiden, Netherlands
London Health Science Centre

London, Ontario, N6A 5B7, Canada
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55902, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Nova Scotia Health

Halifax, Nova Scotia, B3H 2Y9, Canada
Radboud University Medical Centre Interne Geneeskund

Nijmegen, Netherlands
SPZOZ Szpital Uniwersytecki w Krakowie

Krakow, Poland
The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
UC Davis

Sacramento, California, 95817, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States
UZ Leuven

Leuven, Belgium
Universidad Catolica

Santiago, Chile
University Clinical Hospital of Santiago de Compostela/Hospital Universitario

Santiago de Compostela, Spain
University of Alabama

Birmingham, Alabama, 35233, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Missouri

Columbia, Missouri, 65212, United States
Universitário Walter Cantídio

Fortaleza, Brazil
Uniwersyteckie Centrum Kliniczne

Katowice, Poland